The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Open accessPreprint — published as 10.1038/s41586-021-03471-w · Paper page
Abstract
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations and may reduce efficacy of current vaccines targeted at the spike glycoprotein. We re-cently described the emergence of VOC in South Africa (501Y.V2 or PANGO lineage B.1.351) with mutations in the spike receptor-binding domain (RBD) and N-terminal domain (NTD). Here, using a live virus neutralization assay (LVNA), we compared neutralization of a first wave virus (B.1.1.117) versus the 501Y.V2 variant using plasma collected from adults hospitalized with COVID-19 from two South African infection waves, with the second wave dominated by 501Y.V2 infections. Sequencing demonstrated that infections in first wave plasma donors were with viruses harbouring none of the 501Y.V2-defining RBD or NTD mutations, except for one with E484K. 501Y.V2 virus was effectively neutralized by plasma from second wave infections and first wave virus was effectively neutralized by first wave plasma. In cross-neutralization, 501Y.V2 virus was poorly neutralized by first wave plasma, with an 8.4-fold drop in neutralization relative to first wave virus and a 15.1-fold drop relative to 501Y.V2 neutralization by second wave plasma. In contrast, second wave plasma neutralization of first wave virus was more effective, showing 4.1-fold decline relative to 501Y.V2 virus neutralization and 2.3-fold decline relative to first wave plasma neutralization. While we only tested one plasma elicited by E484K alone, this potently neutralized both variants. The observed effective neutralization of first wave virus by 501Y.V2 infection elicited plasma provides preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The E484K mutation has been reported to abolish or substantially reduce neutralization by multiple potent monoclonal antibodies and polyclonal convalescent sera in both wild-type and pseudo-virus neutralization assays.12,13,17,18,22”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [12]
In the citing paper
“A recent report using infectious B.1.351virus showed that plasma samples from six convalescent donors were strongly attenuated against this strain, with half-maximal inhibitory concentration (IC 50 ) values 6-to 200-fold higher than ancestral virus 29 .”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
Katoh, K. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf436 · Cited by 17,027 · cited 3×
“It performs alignment of genotypes in MAFFT [29], 168 phylogenetic tree inference in IQ-Tree20, tree dating and ancestral state construction and annotation 169 (https://github.”
BackgroundMethodInfluentialStructure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · cited 1×
“V2 variant after outgrowth revealed no changes in the RBD 58 or NTD but a deletion in the furin cleavage site (Table S3) commonly observed after in vitro culture 59 in Vero E6 cells [19, 20].”
BackgroundGrifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595 · cited 2×
“However, these vaccines may elicit a broader antibody response and protective T 127 cell immunity [25].”
BackgroundRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 9×
“The combination3 of mutations in the 501Y.V2 variant first detected in South Africa include the N501Y,4 K417N, and E484K mutations in the receptor binding domain (RBD) as well as muta-5 tions in the N-terminal domain (NTD).”
BackgroundInfluentialSelf-citationAntibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · doi:10.1101/2021.01.25.428137 · Cited by 2,328
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · cited 2×
“Plasma 50 samples were from blood drawn approximately 1 month post-symptom onset (Table S1), shown to be 51 close to the antibody response peak [16, 17].”
BackgroundSelf-citationEvolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citationVolz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611 · cited 2×
“[2] Erik Volz, Swapnil Mishra, Meera Chand, Jeffrey C.”
Background
Cited by
Sorted by citations
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Self-citationMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
“351 lineage, which were recently reported to exhibit nearly complete neutralization resistance in response to convalescent plasma (Cele et al., 2021).”
Self-citationGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
“Notably, very recent studies on viruses from these lineages largely confirm these predictions from our mapping (Cele et al., 2021; Rees-Spear et al., 2021; Wibmer et al., 2021).”
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147
Self-citationSensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W., Lam, E. C., Denis, K. J. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.14.21251704 · Cited by 781
“351 lineage, which were recently reported to exhibit nearly complete neutralization resistance in response to convalescent plasma (Cele et al. 2021).”
Self-citationPreliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · doi:10.1101/2021.02.25.21252477 · Cited by 625
“reported to abolish or substantially reduce neutralization by multiple potent monoclonal antibodies and polyclonal convalescent sera in both wild-type and pseudo-virus neutralization assays.(11,12,16,17,21) Additionally, post-vaccination sera derived from volunteers receiving either of”
BackgroundInfluentialSelf-citationEfficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103055 · Cited by 625
Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
SARS-CoV-2 within-host diversity and transmission
Lythgoe, K., Hall, M. D., Luca Ferretti, A., de Cesare, M., MacIntyre-Cockett, G., Trebes, A., Andersson, M. I., Otecko, N. O., Wise, E. L., Moore, N. A., et al. (2021) · Science · doi:10.1126/science.abg0821 · Cited by 389
The variant gambit: COVID-19’s next move
Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.005 · Cited by 273
“351 variant RBDs was minor (often only 2-fold) compared to reported reduction in neutralization (which ranges from 6- to 8-fold to complete loss of neutralization) (Cele et al., 2021; Wibmer et al., 2021; Wu et al., 2021).”
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03594-0 · Cited by 253
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · doi:10.1101/2021.03.07.21252647 · Cited by 651
Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19
Gómez, C. E., Perdiguero, B., & Estéban, M. (2021) · Vaccines · doi:10.3390/vaccines9030243 · Cited by 267
Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, BrazilPreprint
Faria, N., Mellan, T., Whittaker, C., et al. (2021) · medRxiv · doi:10.1101/2021.02.26.21252554 · Cited by 207
A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa
Wilkinson, E., Giovanetti, M., Tegally, H., San, J. E., Lessells, R. J., Cuadros, D. F., Martin, D. P., Rasmussen, D. A., Zekri, A. N., Sangaré, A. K., et al. (2021) · Science · doi:10.1126/science.abj4336 · Cited by 213
Self-citationmRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
(2021) · doi:10.1101/2021.01.15.426911 · Cited by 1,354
Self-citationThe effect of spike mutations on SARS-CoV-2 neutralization
Rees-Spear, C., Muir, L., Griffith, S. A., Heaney, J., Aldon, Y., Snitselaar, J. L., Thomas, P., Graham, C., Seow, J., Lee, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108890 · Cited by 221
“351 have been shown to be resistant to neutralization by a large proportion of convalescent plasma samples (Cele et al., 2021; Wibmer et al., 2021).”
Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
Bian, L., Gao, F., Zhang, J., He, Q., Mao, Q., Xu, M., & Liang, Z. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903879 · Cited by 182
“epitopes for hACE2-blocking neutralizing antibodies [18], which might lead to the ineffectiveness of immune protection provided by previous infections and vaccines [19].”
BackgroundEmerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 156
SARS-CoV-2 evolution and vaccines: cause for concern?
Williams, T., & Burgers, W. A. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00075-8 · Cited by 163
Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
Rella, S. A., Kulikova, Y. A., Dermitzakis, E. T., & Kondrashov, F. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95025-3 · Cited by 139
Jassat, W., Mudara, C., Ozougwu, L., Tempia, S., Blumberg, L. H., Davies, M., Pillay, Y. G., Carter, T., Morewane, R., Wolmarans, M., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00289-8 · Cited by 197
Hodcroft, E. B., Domman, D., Snyder, D. J., Oguntuyo, K. Y., Diest, M. V., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.12.21251658 · Cited by 110
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134
“These confer partial to complete resistance to convalescent plasma and to some monoclonal antibodies (mAbs), including class I/II RBD-directed mAbs and 4A8 which targets the NTD (Wibmer et al., 2021, Cele et al., 2021, Wang et al., 2021a).”
InfluentialSelf-citationCohen, C. A., Li, A. P. Y., Hachim, A., Hui, D. S. C., Kwan, M. Y. W., Tsang, O. T., Chiu, S. S. S., Chan, W. H., Yau, Y. S., Kavian, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24938-4 · Cited by 142
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
“351, 25 serum samples from Group-1 participants who tested seronegative at enrolment but showed varying neutralizing antibody titers at 14 days post 2 dose of injection were assayed using PSVNA and LVNA before unblinding of study arm allocation.(14,21) The PSVNA tested neutralization activity against the original D614…”
BackgroundMethodInfluentialSelf-citationGrabowski, F., Preibisch, G., Giziński, S., Kochańczyk, M., & Lipniacki, T. (2021) · Viruses · doi:10.3390/v13030392 · Cited by 112
“shows that an African variant L18F, D80A, D215G, K417N, E484K, N501Y, D614G, A701V propagates much faster than a variant without L18F mutation in the presence of plasma antibodies collected from donors infected in the first wave of epidemic in South Africa (June–August 2020) [28].”
BackgroundCOVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
He, Q., Mao, Q., Zhang, J., Bian, L., Gao, F., Wang, J., Xu, M., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669339 · Cited by 112
Hypoxic and Pharmacological Activation of HIF Inhibits SARS-CoV-2 Infection of Lung Epithelial Cells
Wing, P. A. C., Keeley, T. P., Zhuang, X., Lee, Y. S., Prange‐Barczynska, M., Tsukuda, S., Morgan, S. B., Harding, A. C., Argles, I. L. A., Kurlekar, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109020 · Cited by 108
“HV001 (Cele et al., 2021) Centre for the AIDS Programme of Research in South Africa SARS-CoV-2 B1.”
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · doi:10.1101/2021.02.23.21252268 · Cited by 291
Self-citationChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
Fischer, R. J., van Doremalen, N., Adney, D. R., Yinda, C. K., Port, J. R., Holbrook, M. G., Schulz, J. E., Williamson, B. N., Thomas, T., Barbian, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26178-y · Cited by 60
Wyllie, D., Jones, H. E., Mulchandani, R., Trickey, A., Taylor-Phillips, S., Brooks, T., Charlett, A., Ades, A., EDSAB-HOME investigators, Moore, P., et al. (2020) · doi:10.1101/2020.11.02.20222778 · Cited by 96
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Tanaka, S., Nelson, G., Olson, C. A., Buzko, O. V., Higashide, W., Shin, A., Gonzalez, M. R., Taft, J. D., Patel, R. S., Buta, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91809-9 · Cited by 65
Redd, A., Nardin, A., Kared, H., et al. (2021) · medRxiv · doi:10.1101/2021.02.11.21251585 · Cited by 65
Cabrera-García, D., Bekdash, R., Abbott, G. W., Yazawa, M., & Harrison, N. L. (2021) · The Journal of Physiology · doi:10.1113/jp281037 · Cited by 78
The ins and outs of SARS-CoV-2 variants of concern (VOCs)
Salehi-Vaziri, ., Fazlalipour, M., Khorrami, S. M. S., Azadmanesh, K., Pouriayevali, M. H., Jalali, T., Shoja, Z., & Maleki, A. (2022) · Archives of Virology · doi:10.1007/s00705-022-05365-2 · Cited by 61
Faulkner, N., Ng, K. W., Wu, M. Y., Harvey, R., Margaritis, M., Paraskevopoulou, S., Houlihan, C., Hussain, S., Greco, M., Bolland, W., et al. (2021) · eLife · doi:10.7554/elife.69317 · Cited by 52
Self-citationRedd, A. D., Nardin, A., Kared, H., Bloch, E. M., Pekosz, A. S., Laeyendecker, O. B., Abel, B., Fehlings, M., Quinn, T. C., & Tobian, A. A. R. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab143 · Cited by 105
Skelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · doi:10.21203/rs.3.rs-226857/v1 · Cited by 216
Zhuang, X., Tsukuda, S., Wrensch, F., Wing, P. A. C., Schilling, M., Harris, J. M., Borrmann, H., Morgan, S. B., Cane, J., Mailly, L., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103144 · Cited by 63
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · medRxiv · doi:10.1101/2021.03.07.21253098 · Cited by 41
“Our data indicate that reduction in binding to the E484K and B.1.351 variant RBDs was minor (often only 2-fold) compared to reported reduction in neutralization (which ranges from 6-8 fold to complete loss of neutralization (Cele et al., 2021; Wibmer et al., 2021; Wu et al., 2021)).”
InfluentialPuente, J. H. L., Carreño, J. M., Sun, W., Suárez-Martínez, A., Ramírez-Martínez, L. A., Quezada-Monroy, F., la Rosa, G. P.-D., Vigueras-Moreno, R., Singh, G., Rojas-Martínez, O., et al. (2021) · mBio · doi:10.1128/mbio.01908-21 · Cited by 46
Greaney, A. J., Starr, T. N., Barnes, C., et al. (2021) · bioRxiv · doi:10.1101/2021.03.17.435863 · Cited by 45
SARS‐CoV‐2 virulence evolution: Avirulence theory, immunity and trade‐offs
Alizon, S., & Sofonea, M. T. (2021) · Journal of Evolutionary Biology · doi:10.1111/jeb.13896 · Cited by 53
“Among these mutations, there was the N501Y substitution found in variant α, but also the E484K mutation, which is associated with immune escape (Cele et al., 2021).”
BackgroundLong, S. W., Olsen, R. J., Christensen, P. A., Subedi, S., Olson, R., Davis, J. J., Saavedra, M. O., Yerramilli, P., Pruitt, L., Reppond, K., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.004 · Cited by 46
Jassat, W., Mudara, C., Ozougwu, L., Tempia, S., Blumberg, L. H., Davies, M., Pillay, Y. G., Carter, T., Morewane, R., Wolmarans, M., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21253184 · Cited by 61
“(7,8) The United Kingdom reported increased hospitalisation and mortality rates in people infected with”
BackgroundLusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 33
Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 37
Butera, Y., Mukantwari, E., Artesi, M., Umuringa, J. D., O’Toole, Á., Hill, V., Rooke, S., Hong, S. L., Dellicour, S., Majyambere, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25985-7 · Cited by 36
Douglas, J., Geoghegan, J. L., Hadfield, J., Bouckaert, R., Storey, M., Ren, X., de Ligt, J., French, N. P., & Welch, D. (2021) · Emerging infectious diseases · doi:10.3201/eid2709.211097 · Cited by 37
“20248640v) (31), no secondary infections were reported, including in case-patient A’s traveling companion.”
BackgroundThe localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York StatePreprint
Lasek‐Nesselquist, E., Lapierre, P., Schneider, E., George, K. S., & Pata, J. D. (2021) · medRxiv · doi:10.1101/2021.02.26.21251868 · Cited by 38
SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
Abdullahi, A., Oladele, D. A., Owusu, M., Kemp, S. A., James, A. B., Salako, A. O., Fink, D., Ige, F. A., Ferreira, I. A. T. M., Meng, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33792-x · Cited by 30
Improving family access to dying patients during the COVID-19 pandemic
Downar, J., & Kekewich, M. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00025-4 · Cited by 35
Hussey, H., Zinyakatira, N., Morden, E., Ismail, M., Paleker, M., Bam, J.-L., London, L., Boulle, A., & Davies, M.-A. (2021) · Gates Open Research · doi:10.12688/gatesopenres.13288.1 · Cited by 27
“However, the science on re-infection is still very unclear, and particularly in the context of emerging variants, this should be interpreted cautiously 23 .”
BackgroundThe Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?
Guo, S., Liu, K., & Zheng, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59137 · Cited by 46
Pattabiraman, C., Prasad, P., George, A., et al. (2021) · medRxiv · doi:10.1101/2021.03.17.21253810 · Cited by 24
Ferreira, I. A. T. M., Lee, C. Y. C., Foster, W. S., Abdullahi, A., Dratva, L. M., Tuong, Z. K., Stewart, B. J., Ferdinand, J. R., Guillaume, S. M., Potts, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112991 · Cited by 30
Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
Amanat, F., Strohmeier, S., Meade, P. S., Dambrauskas, N., Mühlemann, B., Smith, D. J., Vigdorovich, V. I., Sather, D. N., Coughlan, L., & Krammer, F. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001384 · Cited by 20
Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
Byttebier, G., Belmans, L., Alexander, M., Saxberg, B. E. H., Spiegeleer, B. M. J. D., Spiegeleer, A. D., Devreker, N., Praet, J. T. V., Vanhove, K., Reybrouck, R., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1920271 · Cited by 19
“7) jeopardizes the future effectiveness of antibody treatments (and even vaccines) that target the spike protein of the virus [35-37].”
BackgroundSkelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · doi:10.21203/rs.3.rs-226857/v2 · Cited by 216
Self-citationGabitzsch, E., Safrit, J. T., Verma, M., Rice, A., Sieling, P. A., Zakin, L., Shin, A., Morimoto, B., Adisetiyo, H., Wong, R. M. H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.08.416297 · Cited by 17
“Page 3 INTRODUCTION 47 To address the ongoing COVID-19 pandemic (1, 2), particularly in the face of viral evolution 48 and evidence of viral variant resistance to antibodies and convalescent plasma (3-6), we have 49 developed a vaccine anticipated to protect individuals from SARS-CoV-2 that has the potential to 50 not…”
BackgroundFocosi, D., Franchini, M., Joyner, M. J., & Casadevall, A. (2022) · Vox Sanguinis · doi:10.1111/vox.13239 · Cited by 15
Horspool, A. M., Ye, C., Wong, T. Y., Russ, B. P., Lee, K. S., Winters, M. T., Bevere, J. R., Kieffer, T. W., Martínez, I., Sourimant, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.05.442784 · Cited by 22
“CP exhibited some beneficial effects early in the pandemic for critically ill patients (Bloch, 2020; Bloch et al., 2020; Chen et al., 2020), but its utility has recently been called into question (Casadevall et al., 2021; Cele et al., 2021; NIH, 2021; Zhao and He, 2020).”
BackgroundMethodWurtzer, S., Waldman, P., Levert, M., Mouchel, J., Gorgé, O., Boni, M., Maday, Y., Maréchal, V., & Moulin, L. (2021) · medRxiv · doi:10.1101/2021.03.10.21253291 · Cited by 16
Wagner, R., Meißner, J., Grabski, E., Sun, Y., Vieths, S., & Hildt, E. (2021) · Allergy · doi:10.1111/all.14868 · Cited by 25
Sun, D., Sang, Z., Kim, Y. J., et al. (2021) · bioRxiv · doi:10.1101/2021.03.09.434592 · Cited by 18
“These adaptations led to the global emergence of convergent circulating variants of concern, including the UK strain (B.1.1.7), the South Africa strain (B.1.351), and the Brazil strain (P.1) 22-24 .”
Influentialde Oliveira, T., Lutucuta, S., Nkengasong, J. N., Morais, J. F. M., Paixão, J., Neto, Z., Afonso, P., Miranda, J., David, K., Inglês, L., et al. (2021) · medRxiv · doi:10.1101/2021.03.30.21254323 · Cited by 27
Self-citationOutbreaks of publications about emerging infectious diseases: the case of SARS-CoV-2 and Zika virus
Ipekci, A. M., Buitrago‐García, D., Meili, K. W., Krauer, F., Prajapati, N., Thapa, S., Wildisen, L., Araujo-Chaveron, L., Baumann, L., Shah, S., et al. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01244-7 · Cited by 16
“For example, preprint publication in December 2020, about the spread of new more infectious variants of SARS-CoV-2 in the United Kingdom and South Africa [30], provided the scientific evidence for strengthening control measures in several European Countries and changing vaccination policy in South Africa.”
BackgroundMolecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
Hendy, M. A., Kaufman, S., & Ponga, M. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-01081-0 · Cited by 17
Deep dissection of the antiviral immune profile of patients with COVID-19
Atanackovic, D., Avila, S. V., Lutfi, F. U., de Miguel‐Pérez, D., Fan, X., Sanchez‐Petitto, G., Mause, E. R. V., Siglin, J., Baddley, J. W., Mannuel, H. D., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02852-1 · Cited by 10
Lyski, Z. L., Brunton, A., Strnad, M. I., et al. (2021) · medRxiv · doi:10.1101/2021.05.28.21258025 · Cited by 12
“Mutations, particularly those in the receptor binding domain (RBD) on the spike protein, have been shown to increase transmissibility through better binding to the host ACE-2 receptor [13-14] as well as reduce antibody-mediated neutralization by human convalescent immune, COVID-19 vaccine sera [9, 15-19] and therapeut…”
BackgroundMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.006 · Cited by 243
“Importantly, these include the spike variants found in two replication-competent live-virus strains of the B.1.351 lineage, which were recently re-ported to exhibit nearly complete neutralization resistance in response to convalescent plasma (Cele et al., 2021).”
InfluentialSelf-citationGenomic Sequencing of SARS-COV-2 in Rwanda: evolution and regional dynamicsPreprint
Butera, Y., Mukantwari, E., Artesi, M., et al. (2021) · medRxiv · doi:10.1101/2021.04.02.21254839 · Cited by 10
Early super-spreader events are a likely determinant of novel SARS-CoV-2 variant predominance
Goyal, A., Reeves, D., & Schiffer, J. (2021) · medRxiv · doi:10.1101/2021.03.23.21254185 · Cited by 10
Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K
Laiton‐Donato, K., Usme-Ciro, J. A., Franco-Muñoz, C., Álvarez-Díaz, D. A., Ruiz-Moreno, H. A., Reales-González, J., Prada-Cardozo, D., Corchuelo, S., Herrera-Sepúlveda, M. T., Naizaque, J., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.697605 · Cited by 7
“E484K has been suggested to be responsible for a considerably lower neutralizing activity in vitro from convalescent plasma (20, 24, 25), although the cell-mediated immunity could not be affected by the distinctive mutations (26).”
BackgroundClark, J. J., Sharma, P., Bentley, E. G., Harding, A. C., Kipar, A., Neary, M., Box, H., Hughes, G. L., Patterson, E. I., Sharp, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.10.434447 · Cited by 7
Self-citationMultiplex Fragment Analysis Identifies SARS-CoV-2 Variants
Clark, A. E., Wang, Z.-H., Cantarel, B., et al. (2021) · medRxiv · doi:10.1101/2021.04.15.21253747 · Cited by 7
Lien, C., Kuo, T.-Y., Lin, Y., et al. (2021) · medRxiv · doi:10.1101/2021.03.19.21254000 · Cited by 7
SARS-CoV-2 transmission, vaccination rate and the fate of resistant strains
Rella, S. A., Kulikova, Y. A., Dermitzakis, E., & Kondrashov, F. A. (2021) · medRxiv · doi:10.1101/2021.02.08.21251383 · Cited by 6
Chrysanthus, C. S. (2022) · International Journal of Clinical Virology · doi:10.29328/journal.ijcv.1001043 · Cited by 12
“These aggregated mutations in the 501Y, K417N, and E484K were detected in the receptor-binding domain, RBD including mutations in the N-terminal domain, NTD [11].”
BackgroundWhittaker, C., Watson, O. J., Álvarez, C., Angkasekwinai, N., Boonyasiri, A., Triana, L. C., Chanda, D. M., Charoenpong, L., Chayakulkeeree, M., Cooke, G., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab837 · Cited by 8
Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations
Gomez-Martinez, J., Henry, S., Tuaillon, É., de Perre, P. V., Fournier‐Wirth, C., Foulongne, V., & Brès, J.-C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.902914 · Cited by 6
“Multiple studies reported that this mutation reduced neutralizing antibody activity, potentially resulting in immune evasion (Cele et al., 2021; Wibmer et al., 2021).”
BackgroundEspinosa, L. A., Ramos, Y., Andújar, I., Torres, E. O., Cabrera, G., Martin, A. M., Gonzalez-Roche, D., Chinea, G., Béquet‐Romero, M., González, I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.10.443404 · Cited by 4
“SARS-CoV-2 with point mutations (58) or other mutants generated by virus recombination phenomena (59).”
BackgroundImmune dynamics of SARS-CoV-2 virus evolution
Kamat, M., Kurlawala, V., Ghosh, G., & Vaishnav, R. (2022) · International Journal of Molecular and Immuno Oncology · doi:10.25259/ijmio_26_2021 · Cited by 4
Bar‐On, Y. M., Noor, Ε., Gottlieb, N., Sigal, A., & Milo, R. (2021) · medRxiv · doi:10.1101/2021.06.06.21258429 · Cited by 4
Self-citationReview of: "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant"
Lundstrom, K. H. (2021) · Qeios · doi:10.32388/8itiky · Cited by 1
“351 variant was evaluated with pseudovirus and live-virus assays [2,3] in 25 individuals, who were SARS-CoV-2 seronegative at enrolment but showed neutralizing antibody activity against SARS-CoV-2 D614G 14 days after the second vaccination.”
MethodCan proteomics-based approaches further help COVID-19 prevention and therapy?
Kumar, V. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1924684 · Cited by 6
“351 variants also escape neutralization by convalescent plasma, indicating that the mutant virus can evade the immunity generated by prior SARS-CoV-2 infection [7].”
BackgroundFerreira, I., Lee, C. Q., Foster, W., et al. (2022) · medRxiv · doi:10.1101/2022.10.13.22281024 · Cited by 3
Real-time genomics to track COVID-19 post-elimination border incursions in Aotearoa New Zealand
Douglas, J., Geoghegan, J., Hadfield, J., et al. (2021) · medRxiv · doi:10.1101/2021.05.13.21257194 · Cited by 3
Modelling to inform the COVID-19 response in Bangladesh
Ferguson, E. A., Brum, E., Chowdhury, A., et al. (2021) · medRxiv · doi:10.1101/2021.04.19.21255673 · Cited by 3
Metadata
- Authors
- Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell, B. I., Hanekom, W., Moosa, M.-Y. S., NGS-SA, COMMIT-KZN Team, Lessells, R. J., Oliveira, T. D., & Sigal, A.
- Affiliations
- Africa Health Research Institute (ZA)
- Hebrew University of Jerusalem (IL)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of KwaZulu-Natal (ZA)
- Ragon Institute of MGH, MIT and Harvard (US)
- Max Planck Institute for Infection Biology (DE)
- Corresponding author
- Sigal, Alex
- ORCID
- Cele, Sandile
- Gazy, Inbal
- Jackson, Laurelle
- Hwa, Shi-Hsia
- Tegally, Houriiyah
- Lustig, Gila
- Giandhari, Jennifer
- Pillay, Sureshnee
- Wilkinson, Eduan
- Naidoo, Yeshnee
- Karim, Farina
- Ganga, Yashica
- Khan, Khadija
- Bernstein, Mallory
- Balazs, Alejandro B.
- Gosnell, Bernadett I.
- Hanekom, Willem
- Moosa, Mahomed-Yunus S.
- Lessells, Richard J.
- Oliveira, Tulio de
- Sigal, Alex
- Venue
- Nature
- Publisher
- openRxiv
- Published
- 2021-01-26
- Volume
- 593
- Issue
- 7857
- Pages
- 142-146
- ISSN
- 0028-0836 (ISSN-L)
- PMC
- PMC9867906
- OpenAlex
- W3148277587
- Cited by
- 651
- References
- 29
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 28 · 2023: 63 · 2022: 199 · 2021: 320
- FWCI
- 48.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Griffith Research Online (submittedVersion, other-oa)
- Funders
- South African Medical Research Council
- Inyuvesi Yakwazulu-Natali
- National Health Laboratory Service
- Medical Research Council
- National Institute on Drug Abuse (DP2DA040254)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, Beta variant, convalescent plasma, neutralizing antibodies, cross-neutralization, vaccine efficacy, spike protein, receptor binding domain, COVID-19 pandemic, South Africa
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Animals, Antibodies, Viral, Cell Line, Chlorocebus aethiops, Humans, Immunization, Passive, Mutation, Neutralization Tests, South Africa, Time Factors, Vero Cells, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
